[1] | Massano, J., Regateiro, F.S., Januario, G., et al., “Oral squamous cell carcinoma: Review of prognostic and predictive factors”, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 102, 67-76, 2006. |
|
[2] | Acha, A., Ruesga, M.T., Rodríguez, M.J., Martínez-Pancorbo, M.A., Aguirre, J.M, “Applications of the oral scraped (exfoliative) cytology in oral cancer and pre cancer”, Med Oral Patol Oral Cir Bucal, 10, 95-102, 2005. |
|
[3] | Fedele, S., “Diagnostic aids in the screening of oral cancer”, Head Neck Oncol, 30, 1-5, 2009. |
|
[4] | Scully, C., “Oral precancer: prevention and medical approach to management”, Eur J Cancer Oral Oncol, 31, 16-26, 1995. |
|
[5] | Schepman, K., Van der Meji, E.H., Smeele, L., Vander Wall I., “Concomitant leukoplakia in patients with oral squamous cell carcinoma”, Oral Dis, 5, 206-209, 1999. |
|
[6] | Lee, J.J., Hong, W.K, Hittelman, W.N., Lotan, L.R., Shin, D.M. et al, “Predicting cancer development in oral leukoplakia: ten years of translational research”, Clin Cancer Res, 6, 1702, 2000. |
|
[7] | Silverman, S., Gorsky, M., Lozada, F., “Oral leukoplakia and malignant transformation. A follow up study of 257 patients”, Cancer, 53, 563-568, 1984. |
|
[8] | Kim, J., M,Adel-el-Naggar, D., Lee, J.S., Corrales, C., Lippman, S.S., Hong, W.K. and Hittleman, W.N., “ Chromosome polysomy and Histological Characteristics in oral premalignant Lesions”, Cancer epidemiology, Biomarkers and Prevention, 10, 319-325, 2001. |
|
[9] | Dietrich, T., Reichart, P.A., Scheifele, C. “Clinical risk factors of oral leukoplakia in a representative sample of the US population”, Oral Oncol, 40, 158-63, 2004. |
|
[10] | Hollstein, M., Sidransky, D., Vogelstein, B., et al, “p53 mutations in human cancer”, Science, 253, 49-53, 1991. |
|
[11] | Bancroft, J.D., Gamble, M., Theory and Practice of Histological Techniques. Sixth Edition: Elsevier Health Sciences. 2008. |
|
[12] | Dellis, D., Sternberger, L.A., Mann, R.B. et al., “Immunoperoxidase techniques in diagnostics pathology”, American Journal of clinical pathology, 71, 483-8, 1979. |
|
[13] | Raju, B., Mehrotra, R., Oijordsbakken, G. et al., “Expression of p53, CyclinD1 and Ki 67 in pre-malignant and malignant oral lesions: associated with clinic pathological parameters”, Anti cancer, 25, 4699-706, 2005. |
|
[14] | Feulgen,. R, Rossenbeck, H., “Mikrosko pisch chemische Nachweeissliner Nukleinsoure vom Typus Thymonucleinsaure und die daranf beruhende elektive Farbung Von Zellkemen in mikroskopischen praparaten”, Hoppe-Seylers Zeitschrift Physiol Chemie, 135, 203-48, 1924. |
|
[15] | Millet, J.A., Husain, O.A., Bitensky, L., et al., “Fuelgen–hydrolysis profiles in cells exfoliated from the cervix uteri: a potential aid in diagnosis of malignancy”, J Clin Pathol, 35, 345-49, 1982. |
|
[16] | Kumar, V., Rao, N.N., Nair, N.S., “Micronuclei in oral squamous cell carcinoma: A marker of genotoxic damage”, Indian J Dent Res, 11, 101-6, 2000. |
|
[17] | Sarto, F., Finotto, S., Giacomelli, L., Mazzotti, D., Tomanin, R., Levis, A.G., “The micronucleus assay in exfoliated cells of the human buccal mucosa”, Mutagenesis, 2, 11-7, 1987. |
|
[18] | Squamous Cell Cancer of the Neck–Cambridge University Press, Edited by Robert Herman, University Hospital Leuven, Belgium. 2008. |
|
[19] | Napier, S.S., Speight, P.M., “Natural history of potentially malignant oral lesions and conditions: an overview of the literature”, J. Oral Pathol Med, 1, 1-10, 2008. |
|
[20] | Taya, Y., “p53 and the RB protein connected by Cdk–inhibitory proteins”, Jikken Fgaku, 13, 17-18, 1995. |
|
[21] | Kirsch, D.G., Kastan, M.B., “Tumour suppressor p53: implications for tumour development and prognosis”, J. clin. Oncol,; 16, 3158-3168, 1998. |
|
[22] | Sinicrope, F., Ruan, S., Cleary, R., et al., “bcl-2 and p53 oncoprotein during colorectal tumerogenesis”, Cancer Research, 55, 237-41, 1995. |
|
[23] | Mazars, R., Pujel, P., Mondiondi, P. et al., “p53 mutations in ovarian cancer, a late event?” , Oncoprotein, 6(9), 1685-1690, 1991. |
|
[24] | Kyritisis, A.P., Bondy, M.L,, Hess, K.R. et al., “Prognostic Significance of p53 immunoreactivity in patients with glioma”, Clin Cancer Res, 1, 1617-22, 1995. |
|
[25] | Schlüter, C., Duchrow, M., Wohlenberg, C., Becker, M.H., Key, G., Flad, H.D., et al., “The cell proliferation- associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins”, J Cell Bio, 123, 513-22, 1993. |
|
[26] | Risio, M., Lizza, S.C., Ferrari, A., Candeleresi, G.L. and Rossini,F.P., “Immunohistochemical study of epithelial cell proliferation in hyperplastic polyps, adenomas and adenocarcinomas of the large bowel”, Gastroenterology, 94,899-906, 1988. |
|
[27] | Rahmanzadeh, R., Hüttmann, G., Gerdes, J., Scholzen, T.,“Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis”, Cell Prolif, 40(3), 422-30, 2007. |
|
[28] | Steinbeck, R.G., Heselmeyer, K.M., Moberzer, H.B. et al., “The relationship between Proliferating Cell Nuclear Antigen (PCNA), nuclear DNA content and mutant p53 during genesis of cervical carcinoma”, Acta Oncol, 34 (2), 171-6, 1995. |
|
[29] | Yamamoto, H., Yamada, N., Asano, G., et al., “Morphological atypis and clinicopathological factors in colorectal adenoma and cancer using nuclear DNA content, p53 and PCNA”, Nippon Geka Gakkai Zasshi,; 95, 763-74, 1994. |
|
[30] | Speight, P.M., “Update on Oral Epithelial Dysplasia and Progression to Cancer”, Head Neck Pathol,, 1(1), 61-66, 2007. |
|